ATE343573T1 - Epothilonderivate, ihre synthese und verwendung - Google Patents

Epothilonderivate, ihre synthese und verwendung

Info

Publication number
ATE343573T1
ATE343573T1 AT99931120T AT99931120T ATE343573T1 AT E343573 T1 ATE343573 T1 AT E343573T1 AT 99931120 T AT99931120 T AT 99931120T AT 99931120 T AT99931120 T AT 99931120T AT E343573 T1 ATE343573 T1 AT E343573T1
Authority
AT
Austria
Prior art keywords
absent
single bond
synthesis
alkyl
double bond
Prior art date
Application number
AT99931120T
Other languages
English (en)
Inventor
Kyriacos Costa Nicolaou
Nigel Paul King
Maurice Raymond Finlay
Yun He
Frank Roschangar
Dionisios Vourloumis
Hans Vallberg
Antony Bigot
Original Assignee
Novartis Pharma Gmbh
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh, Scripps Research Inst filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE343573T1 publication Critical patent/ATE343573T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Silicon Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99931120T 1998-06-22 1999-06-21 Epothilonderivate, ihre synthese und verwendung ATE343573T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/102,602 US6380394B1 (en) 1996-12-13 1998-06-22 Epothilone analogs

Publications (1)

Publication Number Publication Date
ATE343573T1 true ATE343573T1 (de) 2006-11-15

Family

ID=22290705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931120T ATE343573T1 (de) 1998-06-22 1999-06-21 Epothilonderivate, ihre synthese und verwendung

Country Status (28)

Country Link
US (3) US6380394B1 (de)
EP (2) EP1089998B1 (de)
JP (1) JP4681732B2 (de)
KR (3) KR100864742B1 (de)
CN (1) CN1192031C (de)
AT (1) ATE343573T1 (de)
AU (1) AU757854B2 (de)
BR (1) BR9911420A (de)
CA (1) CA2334342C (de)
CY (1) CY1105863T1 (de)
CZ (1) CZ301783B6 (de)
DE (1) DE69933767T2 (de)
DK (1) DK1089998T3 (de)
ES (1) ES2273502T3 (de)
HK (1) HK1038358A1 (de)
HU (1) HUP0102711A3 (de)
ID (1) ID28210A (de)
IL (3) IL139784A0 (de)
MX (1) MXPA00012443A (de)
NO (1) NO328417B1 (de)
NZ (1) NZ508622A (de)
PL (1) PL197648B1 (de)
PT (1) PT1089998E (de)
RU (1) RU2227142C2 (de)
SK (2) SK285647B6 (de)
TR (1) TR200003844T2 (de)
WO (1) WO1999067252A2 (de)
ZA (1) ZA200007059B (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
PT941227E (pt) * 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (de) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
DE19820599A1 (de) * 1998-05-08 1999-11-11 Biotechnolog Forschung Gmbh Epothilonderivate, Verfahren zu deren Herstellung und deren Verwendung
DE19826988A1 (de) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
AU768220B2 (en) 1998-11-20 2003-12-04 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
ES2209831T3 (es) 1999-02-22 2004-07-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilonas modificadas en c-21.
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1232149A2 (de) * 1999-11-24 2002-08-21 Gesellschaft für biotechnologische Forschung mbH (GBF) Fungizid wirkende melithiazol-derivate
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
AU2001266583A1 (en) * 2000-05-26 2001-12-11 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
ES2395895T3 (es) * 2000-09-22 2013-02-15 Helmholtz-Zentrum für Infektionsforschung GmbH Triazolo-epotilonas
WO2002030356A2 (en) * 2000-10-13 2002-04-18 The University Of Mississipi Synthesis of epothilones and relates analogs
EP1938821B1 (de) 2001-01-25 2016-03-30 Bristol-Myers Squibb Company Formulierung eines Epothilon-Analogs zur Krebsbehandlung
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
HUP0302567A2 (hu) 2001-01-25 2003-12-29 Bristol-Myers Squibb Co. Epotilon analógokat tartalmazó parenterális adagolási formák és eljárás az előállításukra
WO2002066033A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
WO2002066038A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company Treatment of refractory tumors using epothilone derivatives
NZ527557A (en) * 2001-02-27 2005-05-27 Biotechnolog Forschung Gmbh Degradation of epothilones and ethynyl substituted epothilones
ES2384789T3 (es) 2001-03-14 2012-07-12 Bristol-Myers Squibb Company Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
JP2004532888A (ja) * 2001-06-01 2004-10-28 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン誘導体
ES2315399T3 (es) * 2001-08-23 2009-04-01 Novartis Ag Analogos de epotilona ciclobutilo y ciclopropilo.
WO2003026744A1 (en) * 2001-09-25 2003-04-03 Alcon, Inc. The use of epothilones and analogs in conjunction with ophthalmic surgery
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
US20050227300A1 (en) * 2001-12-07 2005-10-13 Atadja Peter W Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
AU2003235761A1 (en) 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) * 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ATE452896T1 (de) 2002-03-12 2010-01-15 Bristol Myers Squibb Co C3-cyanoepothilonderivate
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
AU2003266961A1 (en) * 2002-08-02 2004-02-25 Novartis Ag Epothilone derivatives
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1759115A (zh) * 2002-08-23 2006-04-12 索隆-基特林癌症研究协会 埃坡霉素(epothilone),合成埃坡霉素的中间体,其类似物及其用途
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
KR101406635B1 (ko) 2002-09-23 2014-06-11 브리스톨-마이어스 스큅 컴퍼니 에포틸론 ｂ의 제조, 분리 및 정제 방법, 및 에포틸론 ｂ의 ｘ-선 결정 구조
EP1553938B1 (de) * 2002-10-15 2007-01-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Verwendung von epothilone zur behandlung hyperparathyreoidismus
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
EP1559447A1 (de) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Epothilonen zur Behandlung von neuronalen Konnektivitätsdefekten wie zum Beispiel Schizophrenie und Autismus
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1674098A1 (de) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007015929A2 (en) * 2005-07-27 2007-02-08 University Of Toledo Epothilone analogues
AU2006318284A1 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7653731B2 (en) * 2006-02-24 2010-01-26 Microsoft Corporation Management of connections to external data
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
EP2024362A4 (de) 2006-05-16 2012-01-25 Pharmascience Inc An die iap-bir-domäne bindende verbindungen
EP2089411A4 (de) 2006-12-04 2010-01-27 Univ Illinois Zusammensetzungen und verfahren zur krebsbehandlung mit cupredoxinen und cpg-reicher dna
WO2008098216A2 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
WO2008118327A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Conformationally restrained epothilone analogues as anti-leukemic agents
EP2065054A1 (de) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Kombinationen mit einem Prostaglandin und Verwendungen davon
EP2070521A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanopartikel mit modifizierter Oberfläche
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
JP2011526601A (ja) * 2008-07-03 2011-10-13 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍性化合物
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (de) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
MX2012013100A (es) 2010-05-18 2013-01-22 Cerulean Pharma Inc Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
EP2665493B1 (de) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri-marker, freisetzungs- und extraktionssysteme sowie verfahren zu ihrer herstellung und verwendung
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2924044B1 (de) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinverbindung eines malonsäurederivates mit abgangsgruppe mit amino oder alkylamino
WO2014116594A1 (en) * 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
JP2018534283A (ja) * 2015-10-16 2018-11-22 ウィリアム マーシュ ライス ユニバーシティＷｉｌｌｉａｍ Ｍａｒｓｈ Ｒｉｃｅ Ｕｎｉｖｅｒｓｉｔｙ エポシロン類似体、合成方法、処置方法、およびその薬物結合体
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
PT941227E (pt) 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
EP0977563B1 (de) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
EP1201666A3 (de) 1997-02-25 2003-03-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Seitenkettenmodifizierte Epothilone
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1005465T3 (da) 1997-08-09 2007-11-05 Bayer Schering Pharma Ag Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe

Also Published As

Publication number Publication date
MXPA00012443A (es) 2004-12-03
SK285647B6 (sk) 2007-05-03
IL182744A0 (en) 2007-07-24
KR20090066332A (ko) 2009-06-23
CN1192031C (zh) 2005-03-09
IL139784A0 (en) 2002-02-10
SK287864B6 (sk) 2012-02-03
KR20010083060A (ko) 2001-08-31
SK19712000A3 (sk) 2001-09-11
US6531497B1 (en) 2003-03-11
NO20006378L (no) 2001-02-21
CZ301783B6 (cs) 2010-06-23
CY1105863T1 (el) 2011-02-02
DE69933767D1 (de) 2006-12-07
NO328417B1 (no) 2010-02-15
DE69933767T2 (de) 2007-09-13
US20030203938A1 (en) 2003-10-30
CA2334342C (en) 2012-07-17
HUP0102711A2 (hu) 2001-12-28
EP1089998A2 (de) 2001-04-11
CA2334342A1 (en) 1999-12-29
WO1999067252A3 (en) 2000-03-16
DK1089998T3 (da) 2007-01-15
CZ20004769A3 (cs) 2001-07-11
EP1741715A1 (de) 2007-01-10
KR20080045298A (ko) 2008-05-22
HUP0102711A3 (en) 2002-09-30
BR9911420A (pt) 2001-03-20
AU757854B2 (en) 2003-03-06
PL197648B1 (pl) 2008-04-30
ZA200007059B (en) 2002-01-30
PT1089998E (pt) 2007-01-31
IL182744A (en) 2010-05-17
TR200003844T2 (tr) 2001-04-20
CN1306531A (zh) 2001-08-01
US7579366B2 (en) 2009-08-25
AU4774899A (en) 2000-01-10
JP4681732B2 (ja) 2011-05-11
WO1999067252A2 (en) 1999-12-29
NZ508622A (en) 2003-07-25
HK1038358A1 (en) 2002-03-15
IL139784A (en) 2010-05-17
JP2002518504A (ja) 2002-06-25
PL345327A1 (en) 2001-12-17
ES2273502T3 (es) 2007-05-01
KR100864742B1 (ko) 2008-10-22
ID28210A (id) 2001-05-10
US6380394B1 (en) 2002-04-30
NO20006378D0 (no) 2000-12-14
EP1089998B1 (de) 2006-10-25
RU2227142C2 (ru) 2004-04-20

Similar Documents

Publication Publication Date Title
DE69933767D1 (de) Epothilonderivate, ihre synthese und verwendung
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
DE69907331T2 (de) Fungizide Zusammensetzung enthaltend ein 1,2,3-Thiadiazolderivat sowie deren Verwendung
DK0805148T3 (da) Benzamidoximderivat, fremgangsmåde til fremstilling heraf og anvendelse af baktericid i landbrug og gartneri
AU689304B2 (en) Quinazoline derivative
ATE250573T1 (de) Azetidin- und pyrrolidinderivate
ATE125539T1 (de) 1,4-benzothiazedinderivat.
DE69208408T2 (de) Phenylthioharnstoffderivate und ihre pharmazeutische Verwendung
PL352613A1 (en) Derivatives of benzamide, insecticides for agriculture and horticulture as well as their application
FI852223A0 (fi) Saosom fungicider anvaenda triazoler.
ATE196905T1 (de) Thienyl- und furylpyrrol derivate, deren herstellung und deren verwendung als insektizide und akarizide
ES2125863T3 (es) Control de microorganismos en plantas con 1-hidroximetilpirazoles.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1089998

Country of ref document: EP